[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |
Advanced search

United States Opioid-induced Constipation Market Report 2018

February 2018 | 120 pages | ID: U85E625DD3CEN
QYResearch

US$ 3,800.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
In this report, the United States Opioid-induced Constipation market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025.

Geographically, this report splits the United States market into seven regions:
  • The West
  • Southwest
  • The Middle Atlantic
  • New England
  • The South
  • The Midwest
  • with sales (volume), revenue (value), market share and growth rate of Opioid-induced Constipation in these regions, from 2013 to 2025 (forecast).
United States Opioid-induced Constipation market competition by top manufacturers/players, with Opioid-induced Constipation sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
  • AstraZeneca
  • Takeda Pharmaceutical
  • Valeant Pharmaceuticals International
  • Abbott
  • Bayer
  • Boehringer Ingelheim
  • C.B. Fleet
  • Cosmo Pharmaceuticals
  • Daewoong
  • Daiichi Sankyo
  • GlaxoSmithKline
  • Ironwood Pharmaceuticals
  • Johnson & Johnson
  • Merck
  • Mundipharma
  • Nektar Therapeutics
  • Pfizer
  • Progenics Pharmaceuticals
  • Shionogi
  • SLA Pharma
  • Sucampo
  • Synergy Pharmaceuticals
  • Theravance
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
  • Solid
  • Liquid
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
  • Drugstore
  • Hospital
  • Others
If you have any special requirements, please let us know and we will offer you the report as you want.
United States Opioid-induced Constipation Market Report 2018

1 OPIOID-INDUCED CONSTIPATION OVERVIEW

1.1 Product Overview and Scope of Opioid-induced Constipation
1.2 Classification of Opioid-induced Constipation by Product Category
  1.2.1 United States Opioid-induced Constipation Market Size (Sales Volume) Comparison by Type (2013-2025)
  1.2.2 United States Opioid-induced Constipation Market Size (Sales Volume) Market Share by Type (Product Category) in 2017
  1.2.3 Solid
  1.2.4 Liquid
1.3 United States Opioid-induced Constipation Market by Application/End Users
  1.3.1 United States Opioid-induced Constipation Market Size (Consumption) and Market Share Comparison by Application (2013-2025)
  1.3.2 Drugstore
  1.3.3 Hospital
  1.3.4 Others
1.4 United States Opioid-induced Constipation Market by Region
  1.4.1 United States Opioid-induced Constipation Market Size (Value) Comparison by Region (2013-2025)
  1.4.2 The West Opioid-induced Constipation Status and Prospect (2013-2025)
  1.4.3 Southwest Opioid-induced Constipation Status and Prospect (2013-2025)
  1.4.4 The Middle Atlantic Opioid-induced Constipation Status and Prospect (2013-2025)
  1.4.5 New England Opioid-induced Constipation Status and Prospect (2013-2025)
  1.4.6 The South Opioid-induced Constipation Status and Prospect (2013-2025)
  1.4.7 The Midwest Opioid-induced Constipation Status and Prospect (2013-2025)
1.5 United States Market Size (Value and Volume) of Opioid-induced Constipation (2013-2025)
  1.5.1 United States Opioid-induced Constipation Sales and Growth Rate (2013-2025)
  1.5.2 United States Opioid-induced Constipation Revenue and Growth Rate (2013-2025)

2 UNITED STATES OPIOID-INDUCED CONSTIPATION MARKET COMPETITION BY PLAYERS/SUPPLIERS

2.1 United States Opioid-induced Constipation Sales and Market Share of Key Players/Suppliers (2013-2018)
2.2 United States Opioid-induced Constipation Revenue and Share by Players/Suppliers (2013-2018)
2.3 United States Opioid-induced Constipation Average Price by Players/Suppliers (2013-2018)
2.4 United States Opioid-induced Constipation Market Competitive Situation and Trends
  2.4.1 United States Opioid-induced Constipation Market Concentration Rate
  2.4.2 United States Opioid-induced Constipation Market Share of Top 3 and Top 5 Players/Suppliers
  2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Opioid-induced Constipation Manufacturing Base Distribution, Sales Area, Product Type

3 UNITED STATES OPIOID-INDUCED CONSTIPATION SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2013-2018)

3.1 United States Opioid-induced Constipation Sales and Market Share by Region (2013-2018)
3.2 United States Opioid-induced Constipation Revenue and Market Share by Region (2013-2018)
3.3 United States Opioid-induced Constipation Price by Region (2013-2018)

4 UNITED STATES OPIOID-INDUCED CONSTIPATION SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2013-2018)

4.1 United States Opioid-induced Constipation Sales and Market Share by Type (Product Category) (2013-2018)
4.2 United States Opioid-induced Constipation Revenue and Market Share by Type (2013-2018)
4.3 United States Opioid-induced Constipation Price by Type (2013-2018)
4.4 United States Opioid-induced Constipation Sales Growth Rate by Type (2013-2018)

5 UNITED STATES OPIOID-INDUCED CONSTIPATION SALES (VOLUME) BY APPLICATION (2013-2018)

5.1 United States Opioid-induced Constipation Sales and Market Share by Application (2013-2018)
5.2 United States Opioid-induced Constipation Sales Growth Rate by Application (2013-2018)
5.3 Market Drivers and Opportunities

6 UNITED STATES OPIOID-INDUCED CONSTIPATION PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 AstraZeneca
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Opioid-induced Constipation Product Category, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 AstraZeneca Opioid-induced Constipation Sales, Revenue, Price and Gross Margin (2013-2018)
  6.1.4 Main Business/Business Overview
6.2 Takeda Pharmaceutical
  6.2.2 Opioid-induced Constipation Product Category, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Takeda Pharmaceutical Opioid-induced Constipation Sales, Revenue, Price and Gross Margin (2013-2018)
  6.2.4 Main Business/Business Overview
6.3 Valeant Pharmaceuticals International
  6.3.2 Opioid-induced Constipation Product Category, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Valeant Pharmaceuticals International Opioid-induced Constipation Sales, Revenue, Price and Gross Margin (2013-2018)
  6.3.4 Main Business/Business Overview
6.4 Abbott
  6.4.2 Opioid-induced Constipation Product Category, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Abbott Opioid-induced Constipation Sales, Revenue, Price and Gross Margin (2013-2018)
  6.4.4 Main Business/Business Overview
6.5 Bayer
  6.5.2 Opioid-induced Constipation Product Category, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Bayer Opioid-induced Constipation Sales, Revenue, Price and Gross Margin (2013-2018)
  6.5.4 Main Business/Business Overview
6.6 Boehringer Ingelheim
  6.6.2 Opioid-induced Constipation Product Category, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Boehringer Ingelheim Opioid-induced Constipation Sales, Revenue, Price and Gross Margin (2013-2018)
  6.6.4 Main Business/Business Overview
6.7 C.B. Fleet
  6.7.2 Opioid-induced Constipation Product Category, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 C.B. Fleet Opioid-induced Constipation Sales, Revenue, Price and Gross Margin (2013-2018)
  6.7.4 Main Business/Business Overview
6.8 Cosmo Pharmaceuticals
  6.8.2 Opioid-induced Constipation Product Category, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 Cosmo Pharmaceuticals Opioid-induced Constipation Sales, Revenue, Price and Gross Margin (2013-2018)
  6.8.4 Main Business/Business Overview
6.9 Daewoong
  6.9.2 Opioid-induced Constipation Product Category, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 Daewoong Opioid-induced Constipation Sales, Revenue, Price and Gross Margin (2013-2018)
  6.9.4 Main Business/Business Overview
6.10 Daiichi Sankyo
  6.10.2 Opioid-induced Constipation Product Category, Application and Specification
    6.10.2.1 Product A
    6.10.2.2 Product B
  6.10.3 Daiichi Sankyo Opioid-induced Constipation Sales, Revenue, Price and Gross Margin (2013-2018)
  6.10.4 Main Business/Business Overview
6.11 GlaxoSmithKline
6.12 Ironwood Pharmaceuticals
6.13 Johnson & Johnson
6.14 Merck
6.15 Mundipharma
6.16 Nektar Therapeutics
6.17 Pfizer
6.18 Progenics Pharmaceuticals
6.19 Shionogi
6.20 SLA Pharma
6.21 Sucampo
6.22 Synergy Pharmaceuticals
6.23 Theravance

7 OPIOID-INDUCED CONSTIPATION MANUFACTURING COST ANALYSIS

7.1 Opioid-induced Constipation Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Opioid-induced Constipation

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Opioid-induced Constipation Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Opioid-induced Constipation Major Manufacturers in 2017
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 UNITED STATES OPIOID-INDUCED CONSTIPATION MARKET SIZE (VALUE AND VOLUME) FORECAST (2018-2025)

11.1 United States Opioid-induced Constipation Sales Volume, Revenue Forecast (2018-2025)
11.2 United States Opioid-induced Constipation Sales Volume Forecast by Type (2018-2025)
11.3 United States Opioid-induced Constipation Sales Volume Forecast by Application (2018-2025)
11.4 United States Opioid-induced Constipation Sales Volume Forecast by Region (2018-2025)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer

The report requires updating with new data and is sent in 2-3 business days after order is placed.
LIST OF TABLES AND FIGURES

Figure Product Picture of Opioid-induced Constipation
Figure United States Opioid-induced Constipation Market Size (K Units) by Type (2013-2025)
Figure United States Opioid-induced Constipation Sales Volume Market Share by Type (Product Category) in 2017
Figure Solid Product Picture
Figure Liquid Product Picture
Figure United States Opioid-induced Constipation Market Size (K Units) by Application (2013-2025)
Figure United States Sales Market Share of Opioid-induced Constipation by Application in 2017
Figure Drugstore Examples
Table Key Downstream Customer in Drugstore
Figure Hospital Examples
Table Key Downstream Customer in Hospital
Figure Others Examples
Table Key Downstream Customer in Others
Figure United States Opioid-induced Constipation Market Size (Million USD) by Region (2013-2025)
Figure The West Opioid-induced Constipation Revenue (Million USD) and Growth Rate (2013-2025)
Figure Southwest Opioid-induced Constipation Revenue (Million USD) and Growth Rate (2013-2025)
Figure The Middle Atlantic Opioid-induced Constipation Revenue (Million USD) and Growth Rate (2013-2025)
Figure New England Opioid-induced Constipation Revenue (Million USD) and Growth Rate (2013-2025)
Figure The South of US Opioid-induced Constipation Revenue (Million USD) and Growth Rate (2013-2025)
Figure The Midwest Opioid-induced Constipation Revenue (Million USD) and Growth Rate (2013-2025)
Figure United States Opioid-induced Constipation Sales (K Units) and Growth Rate (2013-2025)
Figure United States Opioid-induced Constipation Revenue (Million USD) and Growth Rate (2013-2025)
Figure United States Opioid-induced Constipation Market Major Players Product Sales Volume (K Units) (2013-2018)
Table United States Opioid-induced Constipation Sales (K Units) of Key Players/Suppliers (2013-2018)
Table United States Opioid-induced Constipation Sales Share by Players/Suppliers (2013-2018)
Figure 2017 United States Opioid-induced Constipation Sales Share by Players/Suppliers
Figure 2017 United States Opioid-induced Constipation Sales Share by Players/Suppliers
Figure United States Opioid-induced Constipation Market Major Players Product Revenue (Million USD) (2013-2018)
Table United States Opioid-induced Constipation Revenue (Million USD) by Players/Suppliers (2013-2018)
Table United States Opioid-induced Constipation Revenue Share by Players/Suppliers (2013-2018)
Figure 2017 United States Opioid-induced Constipation Revenue Share by Players/Suppliers
Figure 2017 United States Opioid-induced Constipation Revenue Share by Players/Suppliers
Table United States Market Opioid-induced Constipation Average Price (USD/Unit) of Key Players/Suppliers (2013-2018)
Figure United States Market Opioid-induced Constipation Average Price (USD/Unit) of Key Players/Suppliers in 2017
Figure United States Opioid-induced Constipation Market Share of Top 3 Players/Suppliers
Figure United States Opioid-induced Constipation Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Opioid-induced Constipation Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Opioid-induced Constipation Product Category
Table United States Opioid-induced Constipation Sales (K Units) by Region (2013-2018)
Table United States Opioid-induced Constipation Sales Share by Region (2013-2018)
Figure United States Opioid-induced Constipation Sales Share by Region (2013-2018)
Figure United States Opioid-induced Constipation Sales Market Share by Region in 2017
Table United States Opioid-induced Constipation Revenue (Million USD) and Market Share by Region (2013-2018)
Table United States Opioid-induced Constipation Revenue Share by Region (2013-2018)
Figure United States Opioid-induced Constipation Revenue Market Share by Region (2013-2018)
Figure United States Opioid-induced Constipation Revenue Market Share by Region in 2017
Table United States Opioid-induced Constipation Price (USD/Unit) by Region (2013-2018)
Table United States Opioid-induced Constipation Sales (K Units) by Type (2013-2018)
Table United States Opioid-induced Constipation Sales Share by Type (2013-2018)
Figure United States Opioid-induced Constipation Sales Share by Type (2013-2018)
Figure United States Opioid-induced Constipation Sales Market Share by Type in 2017
Table United States Opioid-induced Constipation Revenue (Million USD) and Market Share by Type (2013-2018)
Table United States Opioid-induced Constipation Revenue Share by Type (2013-2018)
Figure Revenue Market Share of Opioid-induced Constipation by Type (2013-2018)
Figure Revenue Market Share of Opioid-induced Constipation by Type in 2017
Table United States Opioid-induced Constipation Price (USD/Unit) by Types (2013-2018)
Figure United States Opioid-induced Constipation Sales Growth Rate by Type (2013-2018)
Table United States Opioid-induced Constipation Sales (K Units) by Application (2013-2018)
Table United States Opioid-induced Constipation Sales Market Share by Application (2013-2018)
Figure United States Opioid-induced Constipation Sales Market Share by Application (2013-2018)
Figure United States Opioid-induced Constipation Sales Market Share by Application in 2017
Table United States Opioid-induced Constipation Sales Growth Rate by Application (2013-2018)
Figure United States Opioid-induced Constipation Sales Growth Rate by Application (2013-2018)
Table AstraZeneca Basic Information List
Table AstraZeneca Opioid-induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure AstraZeneca Opioid-induced Constipation Sales Growth Rate (2013-2018)
Figure AstraZeneca Opioid-induced Constipation Sales Market Share in United States (2013-2018)
Figure AstraZeneca Opioid-induced Constipation Revenue Market Share in United States (2013-2018)
Table Takeda Pharmaceutical Basic Information List
Table Takeda Pharmaceutical Opioid-induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Takeda Pharmaceutical Opioid-induced Constipation Sales Growth Rate (2013-2018)
Figure Takeda Pharmaceutical Opioid-induced Constipation Sales Market Share in United States (2013-2018)
Figure Takeda Pharmaceutical Opioid-induced Constipation Revenue Market Share in United States (2013-2018)
Table Valeant Pharmaceuticals International Basic Information List
Table Valeant Pharmaceuticals International Opioid-induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Valeant Pharmaceuticals International Opioid-induced Constipation Sales Growth Rate (2013-2018)
Figure Valeant Pharmaceuticals International Opioid-induced Constipation Sales Market Share in United States (2013-2018)
Figure Valeant Pharmaceuticals International Opioid-induced Constipation Revenue Market Share in United States (2013-2018)
Table Abbott Basic Information List
Table Abbott Opioid-induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Abbott Opioid-induced Constipation Sales Growth Rate (2013-2018)
Figure Abbott Opioid-induced Constipation Sales Market Share in United States (2013-2018)
Figure Abbott Opioid-induced Constipation Revenue Market Share in United States (2013-2018)
Table Bayer Basic Information List
Table Bayer Opioid-induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Bayer Opioid-induced Constipation Sales Growth Rate (2013-2018)
Figure Bayer Opioid-induced Constipation Sales Market Share in United States (2013-2018)
Figure Bayer Opioid-induced Constipation Revenue Market Share in United States (2013-2018)
Table Boehringer Ingelheim Basic Information List
Table Boehringer Ingelheim Opioid-induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Boehringer Ingelheim Opioid-induced Constipation Sales Growth Rate (2013-2018)
Figure Boehringer Ingelheim Opioid-induced Constipation Sales Market Share in United States (2013-2018)
Figure Boehringer Ingelheim Opioid-induced Constipation Revenue Market Share in United States (2013-2018)
Table C.B. Fleet Basic Information List
Table C.B. Fleet Opioid-induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure C.B. Fleet Opioid-induced Constipation Sales Growth Rate (2013-2018)
Figure C.B. Fleet Opioid-induced Constipation Sales Market Share in United States (2013-2018)
Figure C.B. Fleet Opioid-induced Constipation Revenue Market Share in United States (2013-2018)
Table Cosmo Pharmaceuticals Basic Information List
Table Cosmo Pharmaceuticals Opioid-induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Cosmo Pharmaceuticals Opioid-induced Constipation Sales Growth Rate (2013-2018)
Figure Cosmo Pharmaceuticals Opioid-induced Constipation Sales Market Share in United States (2013-2018)
Figure Cosmo Pharmaceuticals Opioid-induced Constipation Revenue Market Share in United States (2013-2018)
Table Daewoong Basic Information List
Table Daewoong Opioid-induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Daewoong Opioid-induced Constipation Sales Growth Rate (2013-2018)
Figure Daewoong Opioid-induced Constipation Sales Market Share in United States (2013-2018)
Figure Daewoong Opioid-induced Constipation Revenue Market Share in United States (2013-2018)
Table Daiichi Sankyo Basic Information List
Table Daiichi Sankyo Opioid-induced Constipation Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Daiichi Sankyo Opioid-induced Constipation Sales Growth Rate (2013-2018)
Figure Daiichi Sankyo Opioid-induced Constipation Sales Market Share in United States (2013-2018)
Figure Daiichi Sankyo Opioid-induced Constipation Revenue Market Share in United States (2013-2018)
Table GlaxoSmithKline Basic Information List
Table Ironwood Pharmaceuticals Basic Information List
Table Johnson & Johnson Basic Information List
Table Merck Basic Information List
Table Mundipharma Basic Information List
Table Nektar Therapeutics Basic Information List
Table Pfizer Basic Information List
Table Progenics Pharmaceuticals Basic Information List
Table Shionogi Basic Information List
Table SLA Pharma Basic Information List
Table Sucampo Basic Information List
Table Synergy Pharmaceuticals Basic Information List
Table Theravance Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Opioid-induced Constipation
Figure Manufacturing Process Analysis of Opioid-induced Constipation
Figure Opioid-induced Constipation Industrial Chain Analysis
Table Raw Materials Sources of Opioid-induced Constipation Major Players/Suppliers in 2017
Table Major Buyers of Opioid-induced Constipation
Table Distributors/Traders List
Figure United States Opioid-induced Constipation Sales Volume (K Units) and Growth Rate Forecast (2018-2025)
Figure United States Opioid-induced Constipation Revenue (Million USD) and Growth Rate Forecast (2018-2025)
Figure United States Opioid-induced Constipation Price (USD/Unit) Trend Forecast (2018-2025)
Table United States Opioid-induced Constipation Sales Volume (K Units) Forecast by Type (2018-2025)
Figure United States Opioid-induced Constipation Sales Volume (K Units) Forecast by Type (2018-2025)
Figure United States Opioid-induced Constipation Sales Volume (K Units) Forecast by Type in 2025
Table United States Opioid-induced Constipation Sales Volume (K Units) Forecast by Application (2018-2025)
Figure United States Opioid-induced Constipation Sales Volume (K Units) Forecast by Application (2018-2025)
Figure United States Opioid-induced Constipation Sales Volume (K Units) Forecast by Application in 2025
Table United States Opioid-induced Constipation Sales Volume (K Units) Forecast by Region (2018-2025)
Table United States Opioid-induced Constipation Sales Volume Share Forecast by Region (2018-2025)
Figure United States Opioid-induced Constipation Sales Volume Share Forecast by Region (2018-2025)
Figure United States Opioid-induced Constipation Sales Volume Share Forecast by Region in 2025
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources

More Publications

Need Help?

Ask a Question

Market Reports

All Categories